Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Cavagna, Lorenzo ^a   Nuño, Laura ^b   Scirè, Carlo Alberto ^c   Govoni, Marcello ^d   Longo, Francisco Javier Lopez ^e   Franceschini, Franco ^f   Neri, Rossella ^g   Castañeda, Santos ^h   Giraldo, Walter Alberto Sifuentes ⁱ   Caporali, Roberto ^a   Iannone, Florenzo ^j   Fusaro, Enrico ^k   Paolazzi, Giuseppe ^l   Pellerito, Raffaele ^m   Schwarting, Andreas ⁿ   Saketkoo, Lesley Ann ^o   Ortego Centeno, Norberto ^p   Quartuccio, Luca ^q   Bartoloni, Elena ^r   Specker, Christof ^s   Murcia, Trinitario Pina ^t   La Corte, Renato ^d   Furini, Federica ^d   Foschi, Valentina ^d   Corral, Javier Bachiller ⁱ   Airò, Paolo ^f   Cavazzana, Ilaria ^f   Martínez Barrio, Julia ^e   Hinojosa, Michelle ^e   Giannini, Margherita ^j   Barsotti, Simone ^g   Menke, Julia ^e,n   Triantafyllias, Kostantinos ^u   Vitetta, Rosetta ^m   Russo, Alessandra ^m   Bajocchi, Gianluigi ^v   Bravi, Elena ^w   Barausse, Giovanni ^l   Bortolotti, Roberto ^l   Selmi, Carlo ^x   Parisi, Simone ^k   Montecucco, Carlomaurizio ^a   González Gay, Miguel Angel ^f,t   Rosenthal, Ken ^y   more..

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Epidemiology Unit   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f SPEDALI CIVILI   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j UNIVERSITY OF BARI   (Italy)

^k CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^l SANTA CHIARA HOSPITAL   (Italy)

^m MAURIZIANO HOSPITAL   (Italy)

ⁿ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^o TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^q SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^r UNIVERSITY OF PERUGIA   (Italy)

^s UNIVERSITY HOSPITAL ESSEN   (Germany)

^t HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^u ACURA Rheumatology Center   (Germany)

^v S MARIA NUOVA HOSPITAL   (Italy)

^w GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^x HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^y NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

JO 1 ANTIBODY; ANTINUCLEAR ANTIBODY; JO-1 ANTIBODY;

ADULT; ANTISYNTHETASE SYNDROME; ARTHRITIS; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE DURATION; EROSION; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOSITIS; OUTCOME ASSESSMENT; POLYARTHRITIS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; RETROSPECTIVE STUDIES;

EID: 84942436488     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001144     Document Type: Article

References (35)

1. Imbert-Masseau A, Hamidou M, Agard C, et al. Antisynthetase syndrome. Joint Bone Spine. 2003; 70: 161-168.
2. Chatterjee S, Prayson R, Farver C. Antisynthetase syndrome: not just an inflammatory myopathy. Cleve Clin J Med. 2013; 80: 655-666.
3. Dugar M, Cox S, Limaye V, et al. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J. 2011; 41: 674-679.
4. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014; 13: 883-891 [PMID: 24704867].
5. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012; 12: 210-217.
6. Lefevre G, Meyer A, Launay D, et al. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxf). 2015; 54: 927-932.
7. Cavagna L, Caporali R, Abdi-Ali L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013; 40: 484-492.
8. Yang CJ, Sheu CC, Ou TT, et al. Combined lung fibrosis and "mechanic's hand": a clinical diagnostic clue to amyopathic antisynthetase syndrome. Respirology. 2008; 13: 611-614.
9. Plastiras SC, Soliotis FC, Vlachoyiannopoulos P, et al. Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. Clin Rheumatol. 2007; 26: 108-111.
10. Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthe-tase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011; 105: 1238-1247.
11. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006; 39: 233-241.
12. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE. 2013; 8: e60442.
13. Cavagna L, Fusetti C, Montecucco C, et al. Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. J Rheumatol. 2010; 37: 1967 author reply 1968.
14. Kaneko Y, Hanaoka H, Hirakata M, et al. Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology (Oxf). 2014; 53: 1120-1124.
15. Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int. 2013; 2013: 759-760.
16. Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol. 2008; 35: 77-83.
17. Ingegnoli F, Galbiati V, Zeni S, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol. 2007; 26: 510-514.
18. Wasicek CA, Reichlin M, Montes M, et al. Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med. 1984; 76: 538-544.
19. Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. 2013; 15: 349.
20. Cavagna L, Prisco E, Montecucco C, et al. Pulmonary arterial hypertension in antisynthetase syndrome: comment on the article by Chatterjee and Farver. Arthritis Care Res (Hoboken). 2011; 63: 633-664 author reply 634.
21. Chatterjee S, Farver C. Severe pulmonary hypertension in anti-Jo-1 syndrome. Arthritis Care Res (Hoboken). 2010; 62: 425-429.
22. Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken). 2013; 65: 800-808.
23. Meyer A, Lefevre G, Bierry G, et al. In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine (Baltimore). 2015; 94: e523.
24. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010; 29: 563-566.
25. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxf). 2003; 42: 1566-1568 [PMID: 14645861].
26. Urata Y, Wakai Y, Kowatari K, et al. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol. 2006; 16: 410-411.
27. Ghirardello A, Zampieri S, Tarricone E, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006; 39: 217-221.
28. Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012; 41: 890-899.
29. Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with anti-synthetase syndrome. Autoimmun Rev. 2012; 11: 739-745.
30. Johnson C, Connors GR, Oaks J, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014; 108: 1542-1548.
31. Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J. 2013; 42: 1271-1282.
32. Mann CJ Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003; 20: 54-60.
33. Song JWCK. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010; 126: 2234-2242.
34. Ascherman D. Animal models of inflammatory myopathy. Curr Rheumatol Rep. 2012; 14: 257-263.
35. Sciorati C, Esposito A, Campana L, et al. 7-Tesla magnetic resonance imaging precisely and noninvasively reflects inflammation and remodeling of the skeletal muscle in a mouse model of antisynthetase syndrome. Biomed Res Int. 2014; 2014: 879703.